"ITP & Me": Your Free Guide for Young Adults and Teens💜 Are you a young person navigating a diagnosis of ITP? This book is for you! ITP and Me – An ITP Book for Young Adults and Teenagers is filled with 48 pages of vital information and, crucially, the real-life experiences of

It's here! 💜 Welcome to the start of Global ITP Awareness Week! This week, the spotlight on Immune Thrombocytopenia shines brighter than ever, reaching across borders and continents. From the UK and all corners of the globe, we stand united with everyone affected by ITP.

ITP is an autoimmune dse in w/c the immune system mistakes the platelets as being foreign & destroys https://t.co/mZVe6FvFw0 we have raised awareness @ImperialNHS &received a lot of engagement from the public @ImperialPeople @NMHaem_Research @nicholacooper @Deenapaul08 @karhod21

#Immune thrombocytopenia is considered an #antibody-mediated disease. However, a number of features suggest alternative methods of #platelet 🩸 destruction, like CD8+ T cell clones studied by Dr. @nicholacooper's team at @ImperialImmuno! @BloodJournal | https://t.co/dTPyYBhmdZ

Good news for some #immunosuppressed #patients - #VROOM study showed #rheumatoid #arthritis patients stopped #methotrexate for 2 weeks they had #CovidVaccine antibody response. Kudos to @TYoungstein for leading the @ImperialNHS part of the trial 1/ https://t.co/ba0fXagpbx

Thank you

Thank you @ImperialCharity for the tickets to @V_and_A corporate evening, we loved it! A great team night out 🎭 #faberge #beatrixpotter #fashioningmasculinities

Efficacy, Safety, Viral Clearance and Antibody Response in those receiving Tocilizumab for COVID-19 pneumonia Important and unique data not collected by the other large trials https://t.co/wb7cfKPtR3 @nicholacooper @bhagani_sanjay @sinisauksav and co @Roche

Great collaboration with @ee_davenport, @nicholacooper and Graham P Taylor, and shoutout to Katie L Burnham and @AllisonMaher6 who did most of the work!

⁦@nicholacooper⁩ Back in venue, register now for ITP Update Day - Friday 6th May at https://t.co/xWfr5eXpIs

You can download a copy for FREE of our highly regarded - Making the right choices in ITP management and care

We are delighted to announce that the @RCPhysicians have reviewed and endorsed the clinical content of our ITP shared decision-making toolkit. The toolkit can be downloaded at https://t.co/VhvD9vCcKR or email info@itpsupport.org.uk for a hard copy.”

Fostamatinib: Ruxolitinib: SoC in COVID-19 patients from admission. @imperialcollege @ImperialNHS study now multi-site @ImperialBRC @ImperialImmuno Plus @RigelPharma +ve top line data on primary safety end point with Fostamatinib in COVID-19

Full video here: https://t.co/FkfbKEtSjP (No I don’t appear 😉)

Truly wonderful video of clinical research @ImperialNHS @ImperialMed #COVID19 research including our evidence based Treatment group. Proud to be a small part of this: @hannahpluthero @grahamscooke @MGilchrist123 @kidneydoc101 @nicholacooper @agordonICU @MATISTrial @remap_cap

So is there any way we prevent this? Yes, there may be! We identified that the drug fostamatinib (Syk inhibitor) can specifically counteract all of these effects. This drug is now in Phase 3 clinical trials, after successful Phase 2: https://t.co/kIJat9TPo9 8/14

Reason #2: in severe COVID-19 patients, the Fc tail of anti-Spike IgG is aberrantly glycosylated (different sugar groups). For details see our previous study in @ScienceMagazine: https://t.co/NTRsYCnjBD 7/14

Paper in Journal of Thrombosis and Haemostasis comparing 43 samples tested for VITT using 10 different assays. Clearly shows that you should be using a HIT ELISA assay. https://t.co/Y8C3zhszor #VITT

MATIS trial protocol published as a structured summary out now here: https://t.co/VxCuORpp92 @DrAWhittington @VR_Cornelius @CharaniaA @NikhilVergis @nicholacooper @rachelpips @andrewinnes007 @melaniesayshi @TYoungstein

https://t.co/Ek91tTDIfo